세포 건강 스크리닝 시장 성장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Cellular Health Screening Market reached a valuation of USD 3.3 billion in 2023 and is projected to grow at a 10.1% CAGR from 2024 to 2032. Advances in cellular health testing technologies have significantly enhanced the ability to monitor and assess cellular function and integrity. Innovations in molecular biology, biochemistry, and bioinformatics have driven these advancements, leading to more precise and comprehensive evaluations of cellular health. Modern technologies like next-generation sequencing (NGS) and mass spectrometry have greatly improved the detection and quantification of biomarkers related to cellular health. These technologies enable high-resolution analysis of metabolites, proteins, and genetic material.

Advanced NGS platforms can analyze thousands of genetic variants simultaneously, offering valuable insights into genetic predispositions and cellular responses to stress. The multi-test panels segment dominated the market in 2023, generating revenue of USD 2 billion. Multi-test panels allow for the simultaneous analysis of various biomarkers, providing a more holistic view of an individual's cellular health. This approach uncovers a spectrum of potential health concerns and paints a complete picture of overall well-being.

Consolidating various tests into a single panel streamlines the diagnostic process, reducing the need for multiple appointments and sample collections. This efficiency saves time for both patients and healthcare providers, driving the adoption of multi-test panels. Integrating multiple assays into one panel often lowers overall testing costs and enhances resource utilization. The blood samples segment held a substantial market share of 36.5% in 2023. Blood samples offer a wealth of information regarding cellular health, encompassing biomarkers, genetic material, and metabolic products.

This extensive data aids in evaluating overall health and pinpointing specific concerns. Blood tests can detect changes in cellular markers at an early stage, which is crucial for the early diagnosis of diseases. Early identification of these changes allows healthcare providers to intervene sooner, leading to better outcomes and more effective treatments. Their high sensitivity and specificity enable precise disease detection, supporting accurate diagnosis and effective monitoring of health conditions, thus contributing to the growth of the blood samples segment.

The U.S. market for cellular health screening is projected to reach USD 2.7 billion by 2032. The rising prevalence of seasonal allergies, eczema, and food allergies in the U.S. underscores the need for cellular health screening tests such as inflammation tests. According to the CDC, 25.7% of adults had seasonal allergies, 7.3% had eczema, and 6.2% had food allergies in 2021. This has driven the demand for inflammation testing as part of a preventive health approach in the U.S. The U.S. is home to leading companies and research institutions that drive innovation in cellular health screening technologies. This includes cutting-edge tools and techniques for analyzing cellular and molecular data.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing emphasis on preventive health screening
    • 3.2.1.2 Advances in cellular health testing technologies
    • 3.2.1.3 Growing demand for personalized medicine
    • 3.2.1.4 Rising demand for direct-to-consumer screening kits
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited reimbursement coverage
    • 3.2.2.2 Lack of standardization
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Single test panels
  • 5.2.1 Telomere tests
  • 5.2.2 Oxidative stress tests
  • 5.2.3 Inflammation tests
  • 5.2.4 Heavy metals tests
• 5.3 Multi-test panels

Chapter 6 Market Estimates and Forecast, By Sample Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Blood samples
• 6.3 Saliva samples
• 6.4 Serum samples
• 6.5 Urine samples

Chapter 7 Market Estimates and Forecast, By Collection Site, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 At-home
• 7.3 In-office
• 7.4 Hospitals
• 7.5 Diagnostic laboratories

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Atomo Diagnostics
• 9.2 Cell Science Systems
• 9.3 Cleveland HeartLab, Inc.
• 9.4 DNA Labs India
• 9.5 Genova Diagnostics
• 9.6 GRAIL, Inc.
• 9.7 Immundiagnostik AG
• 9.8 Laboratory Corporation of America Holdings
• 9.9 OmegaQuant
• 9.10 OPKO Health, Inc.
• 9.11 Quest Diagnostics Inc.
• 9.12 RepeatDx
• 9.13 Segterra, Inc.
• 9.14 SpectraCell Laboratories
• 9.15 Telomere Diagnostics, Inc.